Early phase clinical trial protocols to evaluate safety and immunogenicity of human papillomavirus VLP based vaccines

Ended Definitive Contract Awarded Last action

Contract number
00261200309D261037121
Awardee
Not on record
Awarding agency
Obligated
$793,450

Award facts

Contract value 21% obligated
$3,691,644.00 Current and potential, with all options
Completion date 100% complete
Current and potential, with all options
NAICS code
Not on record
Set-aside
No set-aside
Competition
Not Competed · 1 offer
Pricing
Cost No Fee
Place of performance
Baltimore, MD 21218, USA

Award details come from SAM.gov/FPDS.

Transactions

Action Obligated Date
Other Administrative Action 5 $0
Funding Only Action 6 -$36,576
Supplemental Agreement for work within scope 4 $0
Other Administrative Action 3 $0
Funding Only Action 2 $398,904
Other Administrative Action 1 $0
Original award $394,546

About this award

This is a definitive contract awarded by a U.S. government agency to conduct an early phase clinical trial to evaluate the safety and immunogenicity of human papillomavirus (HPV) virus-like particle (VLP) based vaccines. The contract has a ceiling value of $3,691,644.00 and a completion date of September 30, 2008. It is a cost-no-fee type contract with the place of performance located in Baltimore, Maryland. The contract does not have a set-aside designation. Additional details about the prime contractor, major subcontractors, or the funding agency are not provided.

Quick answers

How much is contract 00261200309D261037121 worth?

The government has obligated $793,450 on 00261200309D261037121. Its current value, with exercised options, is $3,691,644.

Was contract 00261200309D261037121 competed?

The extent of competition for 00261200309D261037121 was not competed. The government received 1 offer.

On GovTribe

See this award's full record

  • Every transaction and funding action
  • The awardee's other awards and teaming partners
  • Similar awards and recompete opportunities
  • Ask GovTribe AI about this award